Clinical data | |
---|---|
Trade names | Lamprene |
Other names | N,5-bis(4-chlorophenyl)-3-(1-methylethylimino)-5H-phenazin-2-amine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682128 |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 70 days |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.016.347 |
Chemical and physical data | |
Formula | C27H22Cl2N4 |
Molar mass | 473.40 g·mol−1 |
3D model (JSmol) | |
Melting point | 210 to 212 °C (410 to 414 °F) |
| |
| |
(what is this?) (verify) |
Clofazimine, sold under the brand name Lamprene, is a medication used together with rifampicin and dapsone to treat leprosy.[1] It is specifically used for multibacillary (MB) leprosy and erythema nodosum leprosum.[2] Evidence is insufficient to support its use in other conditions[1] though a retrospective study found it 95% effective in the treatment of Mycobacterium avium complex (MAC) when administered with a macrolide and ethambutol,[3] as well as the drugs amikacin and clarithromycin.[4] However, in the United States, clofazimine is considered an orphan drug, is unavailable in pharmacies, and its use in the treatment of MAC is overseen by the Food and Drug Administration.[5] It is taken orally.[1]
Common side effects include abdominal pain, diarrhea, itchiness, dry skin, and change in skin color.[1] It can also cause swelling of the lining of the gastrointestinal tract, increased blood sugar, and sensitivity to the sun.[2] It is unclear if use during pregnancy is safe.[1] Clofazimine is a phenazine dye and is believed to work by interfering with DNA.[1]
Clofazimine was discovered in the 1950s at Trinity College, Dublin,[6] and approved for medical use in the United States in 1986.[1] It is on the World Health Organization's List of Essential Medicines.[7] In the United States it is not available commercially but can be obtained from the US Department of Health and Human Services.[1]
By 1954 related molecules known as iminophenazines were being investigated... one of the first ones to be made, originally given the laboratory code B663 ... B663—subsequently called clofazimine